CytomX Therapeutics Inc (CTMX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$2.14-8.94%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · CTMX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 103.4% |
| Our one-year growth estimate | diamond | 55.3% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 48.1 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-11-05 · Compared with 117 industry peers
CTMX — director transition
Dated 2026-07-27
Director — Charles Fuchs, M.D., M.P.H.: Dr. Charles Fuchs was appointed to the Board of Directors as a Class II director.
Why it matters: The update can guide dose choice and the planned late-line CRC trial. Strong results would support the next trial step.
Supportive ifBy December 31, 2026, CytomX reports dose data from the 40-patient study. It names a dose for late-stage testing.
Worry ifThe update slips past year-end, or CytomX reports no dose it can advance to late-stage testing.
Why it matters: Agreement on the trial plan would support the goal of starting it in 1H 2027. No clear path could delay that step.
Supportive ifCytomX reports FDA alignment on the design and path for its first Varseta-M CRC trial, then starts it by June 30, 2027.
Worry ifCytomX reports no agreed trial plan, or the trial has not started by June 30, 2027.
Why it matters: CytomX plans several drug trials and had $330.3 million in cash and investments at Q2 end. A shorter runway could limit those plans.
Worry ifCytomX cuts its stated cash runway to before the second half of 2028, or reports cash and investments below $300 million.
Less concerning ifCytomX keeps its runway at least through 2H 2028 and reports cash and investments of $300 million or more.
Why it matters: The first data will test this drug pair in advanced melanoma. Clear signs of benefit and tolerable side effects would support more study.
Supportive ifBy June 30, 2027, CytomX reports early combination data. It shows signs of tumor response and no new safety issue that stops dose testing.
Worry ifThe data show no tumor responses, a serious safety issue, or a delay past June 30, 2027.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$260 on $10,000 · ±2.6% | How much price usually moves either way. |
| Bad day | $699 loss on $10,000 · 7.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,830 loss on $10,000 · 68.3% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.